The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study
Abstract
No abstract availableKeywords
Funding Information
- Australian Government Department of Health
- Australian National Health and Medical Research Council (APP1000986)
This publication has 40 references indexed in Scilit:
- Bone Mineral Density Changes Among Women Initiating Proton Pump Inhibitors or H2 Receptor Antagonists: A SWAN Cohort StudyJournal of Bone and Mineral Research, 2014
- Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA studyMaturitas, 2014
- The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos)American Journal of Gastroenterology, 2012
- Overutilization of proton-pump inhibitors: what the clinician needs to knowTherapeutic Advances in Gastroenterology, 2012
- Meta-analysis: Risk of fractures with acid-suppressing medicationBone, 2011
- Prescribing of anti‐osteoporotic therapies following the use of proton pump inhibitors in general practicePharmacoepidemiology and Drug Safety, 2010
- Proton Pump Inhibitor Use, Hip Fracture, and Change in Bone Mineral Density in Postmenopausal WomenArchives of internal medicine (1960), 2010
- Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density LossGastroenterology, 2010
- Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older AdultsCalcified Tissue International, 2008
- Use of proton pump inhibitors and risk of osteoporosis-related fracturesCanadian Medical Association Journal, 2008